• Product NameSR-3029
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivitySR 3029 is a potent and highly specific CK1δ/CK1ε inhibitor with the IC50 of 97 nM. SR-3029 exhibits in vitro and in vivo PK properties suitable for use in xenograft studies of human cancers, including brain cancers. Meanwhile it can also Inhibits Breast Cancer Cell Growth and Survival and impairs orthotopic breast tumor growth in vivo. In animal injection, SR-3029 (20 mg/kg daily i.p.)
• Target NameCasein Kinase inhibitor
• CAS No. 1454585-06-8
• Calculated MW 480.45
• Formulation C23H19F3N8O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:C1COCCN1C2=NC3=C(C(=N2)NCC4=NC5=C(N4)C=CC(=C5F)F)N=CN3C6=CC(=CC=C6)F
  Pathways:Metabolism; Stem Cells
  Receptor:CK1δ
  Boling pt:
  Melting pt:
  Solubility:DMSO: 30 mg/Ml
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Rosenberg LH,et al. Therapeutic targeting of casein kinase 1δ in breast cancer. Sci Transl Med. 2015 Dec 16;7(318):318ra202.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting